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INTRODUCTION
Melanins are pigment granules that provide the color for human
hair, skin and eyes, and serve to protect surrounding cells from the
DNA-damaging effects of ultraviolet (UV) light. Melanins are
synthesized and stored in the melanosomes, specialized lysosome-
related organelles of the melanocytes that are transferred to
surrounding skin or hair cells or concentrated within the retinal
pigmented epithelium (Raposo and Marks, 2007). The restriction
of melanosome biogenesis to melanocytes results from the cell-
specific expression and production of pigment enzymes coupled
with their trafficking through the Golgi and early endosomal
pathways to the maturing melanosomal organelles. For example,
the melanocyte regulator Mitf promotes expression of the rate-
limiting enzyme tyrosinase, which is directed through the Golgi
and then to the endosome-to-melanosome pathway by the AP1 and
AP3 adaptor complexes. Once at the melanosome, tyrosinase
promotes melanin synthesis and deposition along the Pmel fibrillar
matrix (Chin et al., 2006; Raposo and Marks, 2007).
Copper (Cu2+) is essential for melanin production, and
consequently hypopigmentation is a feature of copper deficiency.
Genetic mutations of the copper transporters ATP7A or ATP7B
lead to Menkes disease or Wilson’s disease, respectively; these
childhood syndromes cause acute clinical symptoms in the bone,
skin, hair, blood and nervous system (Madsen and Gitlin, 2008).
The transporters ATP7A and ATP7B reside in the trans-Golgi
network and shuttle copper from the cytoplasm to copper-
dependent enzymes in the Golgi. Environmental conditions can
also lead to copper deficiency. For example, lambs born to ewes
feeding on copper-deficient grass share many clinical features with
children diagnosed with Menkes disease; this observation
established copper-metabolism deficiencies as an underlying cause
of the pathology of Menkes disease (Danks et al., 1972). Copper
deficiency can also occur in patients undergoing gastric surgery or
after excessive consumption of zinc or iron, all of which can inhibit
absorption of copper through the intestine (Kumar, 2006). However,
as the causes of many cases of copper deficiency remain unknown
(Madsen and Gitlin, 2007b), a more systematic approach to
understanding copper-metabolism deficiency in humans is
required, including the development of robust cell and animal
models (Thiele and Gitlin, 2008).
Melanocytes have a cell-type-specific requirement for copper in
pigmentation because tyrosinase is a copper-dependent enzyme,
and its activity is dependent on ATP7A (Petris et al., 2000).
Transport of ATP7A into melanosomes spatially restricts melanin
synthesis to melanocytes; this process is dependent on the
biogenesis of the lysosome-related organelle complex (BLOC)-1,
which is required for exit of endosomal cargo (Setty et al., 2008).
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SUMMARY
Hypopigmentation is a feature of copper deficiency in humans, as caused by mutation of the copper (Cu2+) transporter ATP7A in Menkes disease,
or an inability to absorb copper after gastric surgery. However, many causes of copper deficiency are unknown, and genetic polymorphisms might
underlie sensitivity to suboptimal environmental copper conditions. Here, we combined phenotypic screens in zebrafish for compounds that affect
copper metabolism with yeast chemical-genetic profiles to identify pathways that are sensitive to copper depletion. Yeast chemical-genetic interactions
revealed that defects in intracellular trafficking pathways cause sensitivity to low-copper conditions; partial knockdown of the analogous Ap3s1
and Ap1s1 trafficking components in zebrafish sensitized developing melanocytes to hypopigmentation in low-copper environmental conditions.
Because trafficking pathways are essential for copper loading into cuproproteins, our results suggest that hypomorphic alleles of trafficking components
might underlie sensitivity to reduced-copper nutrient conditions. In addition, we used zebrafish-yeast screening to identify a novel target pathway
in copper metabolism for the small-molecule MEK kinase inhibitor U0126. The zebrafish-yeast screening method combines the power of zebrafish
as a disease model with facile genome-scale identification of chemical-genetic interactions in yeast to enable the discovery and dissection of complex
multigenic interactions in disease-gene networks.
Combined zebrafish-yeast chemical-genetic screens
reveal gene–copper-nutrition interactions that
modulate melanocyte pigmentation
Hironori Ishizaki1,*, Michaela Spitzer2,*, Jan Wildenhain2, Corina Anastasaki1, Zhiqiang Zeng1, Sonam Dolma3,‡, Michael Shaw4,
Erik Madsen5, Jonathan Gitlin5, Richard Marais6, Mike Tyers2,3 and E. Elizabeth Patton1,§
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Excess exogenous copper can restore pigmentation to BLOC-1-
deficient melanocytes in vitro (Setty et al., 2008). Components of
BLOC-1 are mutated in Hermansky-Pudlak syndrome (HPS), a
disorder characterized by defects in lysosome-related organelles,
particularly melanosomes and platelet-dense granules (Wei, 2006).
Aberrant transport of ATP7A might be responsible for the HPS
pathology of melanocytes from BLOC-1-deficient individuals (Setty
et al., 2008). In zebrafish, mutation of atp7a or treatment with the
copper-chelator neocuproine causes a phenotype with features of
Menkes disease, including hypopigmentation, neurological
disorders, and loss of lysyl oxidase cuproenzyme activity in the
developing notochord (Mendelsohn et al., 2006). In zebrafish,
hypomorphic alleles of atp7a and the vacuolar ATPase (v-ATPase)
cause hypopigmentation at low copper concentrations,
demonstrating that genetic mutations can result in copper-
deficiency symptoms in suboptimal nutrient conditions (Madsen
and Gitlin, 2008).
We have developed a coupled zebrafish phenotypic and yeast
chemical-genetic screening approach to identify novel genetic
pathways that underlie copper-nutrient sensitivity in the developing
vertebrate melanocyte (Fig. 1A). Phenotypic chemical screens in
zebrafish enable the identification of novel biological pathways by
virtue of chemically induced phenotypes (Zon and Peterson, 2005).
Such zebrafish screens are typically carried out by treating
developing embryos with libraries of small molecules to identify
compounds that elicit a specific phenotype. The small size and
transparency of the embryo, which can be arrayed in 96-well plates,
coupled with tractable genetic tools for target validation and
disease modelling make the zebrafish a highly effective system for
phenotype-driven small-molecule screens. However, despite its
tractability, identification of the target pathways in zebrafish is
usually arduous (Peterson, 2008). Chemical-genetic approaches in
the budding yeast Saccharomyces cerevisiae can provide rich
functional information on the mechanism of action of compounds
dmm.biologists.org640
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Fig. 1. A combined zebrafish and yeast approach to probe chemical-genetic interactions in melanocyte pigmentation. (A)Overview of work flow.
Phenotypic screening in zebrafish informs as to the developmental and physiological target pathway. Small molecules that promote similar phenotypes in
zebrafish are then tested in genome-wide chemical-genetic screens in yeast to reveal potential target genetic pathways. Conserved target pathways are then
directly re-tested for chemical-genetic interactions in the zebrafish system using genetic mutant lines, morpholino oligonucleotides or small molecules known to
impinge on the same target. (B)Phenotypic screening of a >1500-compound yeast-bioactive library (S.D., J.W., M. Spitzer and M.T., unpublished data) and the
Sigma LOPAC library for altered pigmentation in zebrafish embryos revealed a copper-metabolism phenotype characterized by hypopigmentation, an expanded
hindbrain and an undulating notochord (Mendelsohn et al., 2006). Representative phenotype caused by 10M JFD00692 was rescued by treatment with
exogenous copper chloride (5M or 15M) during development. (C)Examples of the copper-metabolism phenotype induced by some of the compounds
identified in the screen.
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(Boone et al., 2007; Hillenmeyer et al., 2008). Mutations that render
yeast sensitive to a particular compound – that is, chemical-genetic
interactions – often establish links to the cellular target pathways
(Hartwell et al., 1997; Parsons et al., 2004; Parsons et al., 2006). The
yeast genome-wide gene-deletion collection, in which each of the
~6000 genes has been individually replaced with a deletion cassette
marked with unique sequence identifiers (barcodes) that can be
quantified in parallel by microarray hybridization, is a powerful
resource for chemical genetics (Winzeler et al., 1999; Giaever et
al., 2002). Chemical-genetic profiling, whereby growth of the
pooled deletion collection is scored for hypersensitivity to a
compound, enables the identification of target and off-target
pathways. This approach has been used to interrogate the
mechanism of action of both novel and clinically approved drugs,
including chemotherapeutics and neuroleptics (Lum et al., 2004;
Parsons et al., 2004; Parsons et al., 2006; Ericson et al., 2008;
Hillenmeyer et al., 2008). Compounds with similar chemical-
genetic profiles can be grouped to reveal similar modes of action
and similar targets (Parsons et al., 2006; Hillenmeyer et al., 2008).
Often the gene networks that confer sensitivity or resistance to a
given compound are conserved from yeast to mammalian cells
(Ericson et al., 2008; Yu et al., 2008).
We identified a novel panel of compounds that affect pathways
of copper metabolism and pigmentation in zebrafish and then
interrogated the mode of action of several of these compounds.
Based on the identification of target genes in yeast encoding
intracellular transport proteins, we show that reduced expression
of the orthologous target genes, ap1s1 and ap3s2, in zebrafish cause
hypopigmentation specifically under conditions of copper
limitation. We also demonstrate that the commonly used MEK
inhibitor U0126 affects copper metabolism in zebrafish, and use
chemical-genetic profiles in yeast to show that U0126 has at least
two target pathways in vivo. This combined zebrafish-yeast
chemical-genetic approach should be applicable to the study of
many other processes associated with disease and development.
RESULTS
A chemical screen identifies small molecules that elicit a copper-
deficiency phenotype in zebrafish
Using phenotypic screening in zebrafish, we identified a panel of
45 small molecules that caused a phenotype characteristic of
copper depletion (Fig. 1; Table 1). We screened the 1280-member
Library of Pharmacologically Active Compounds (LOPAC) and a
collection of 1576 bioactive compounds (S.D., J.W., M. Spitzer and
M.T., unpublished data) for effects on zebrafish pigmentation. Two
embryos at 4 hours post-fertilization (hpf) were placed in each well
of a 96-well plate and treated with 10 M of compound and
observed at multiple time points over 48 hours for a copper-
metabolism phenotype as exemplified by the atp7a-mutant
zebrafish or treatment with neocuproine. These phenotypic
manifestations include hypopigmentation, an expanded hindbrain
and an undulating notochord in a 2- to 3-day-old fish (Fig. 1B).
Active compounds included known copper-binding molecules,
such as 1-phenyl-3-(2-thiazolyl)-2-thiourea (PTT) (Mendelsohn et
al., 2006), as well as the metal-binding thiosemicarbazones, thiourea
derivates, phenanthrolines and pyridin-pyrimidinones (Fig. 1B).
Unexpectedly, the commonly used MEK inhibitor U0126 was also
identified as causing a phenotype consistent with defective copper
metabolism (Table 1); this phenotypic effect of U0126 has been
recently described elsewhere (Hawkins et al., 2008).
Further phenotypic characterization showed the copper-
metabolism phenotype caused by many of the small molecules
could be prevented with the addition of exogenous copper,
indicating that the characteristic zebrafish Menkes phenotypes in
pigmentation, notochord, blood and hindbrain development are
dependent upon the loss of environmental copper availability (Fig.
1B; Table 1). Interestingly, three compounds caused hypersensitivity
to exogenous copper addition (Table 1; supplementary material Fig.
S1). One possibility is that these three compounds interfere with
detoxification of excess copper ions in the cell; elevated copper
levels are highly toxic, and intracellular levels are finely balanced
by copper chaperones and metallothionein levels (Rae et al., 1999).
Genome-wide genetic-sensitivity profiles reveal potential copper-
metabolism pathways
We then used yeast chemical-genetic profiles to identify gene
deletions that resulted in sensitivity to a selected subset of
compounds that affected copper metabolism in our zebrafish
screen: this copper-metabolism subset (CM subset) comprised the
compounds neocuproine, U0126, DP00477, SEW01049, SPB07427,
JFD00692 and RJF01649. Evolutionarily conserved genetic pathways
that are sensitive to copper nutrition in yeast could then be directly
tested in the zebrafish vertebrate system (Fig. 1A). We screened
pools of ~5000 haploid yeast deletion mutants and ~1000
heterozygous diploid mutants for growth after treatment with the
CM subset. Compound concentrations were titrated such that
overall growth of the yeast pool was diminished by 20-30% (Parsons
et al., 2006). Aliquots of the deletion pools were grown for 20
generations in the presence of the different compounds as specified
in supplementary material Table S1 or in the presence of 0.4%
DMSO (control samples). Genomic DNA was isolated from each
pool, the barcodes were amplified with fluorescently labeled
primers, and the PCR products were hybridized to spotted
oligonucleotide microarrays (Cook et al., 2008). Scatter plots
demonstrated that for most chemical-genetic screens, the majority
of deletion mutants were not affected by treatment with compound
(supplementary material Fig. S2). Boxplots and quantile statistics
of z-scores for each microarray allowed identification of sensitive
and resistant mutants (see Methods).
Although all the chemicals in the CM subset produced a similar
developmental atp7a-mutant phenotype in zebrafish, we found
both distinct and common genetic pathways in yeast to be sensitive
or resistant to individual compounds in the CM subset, reflecting
the unique action of each chemical (Fig. 2). First, we examined the
sensitivity of deletions in genes known to be involved in copper
uptake and metabolism. Deletion strains defective in copper
metabolism are in fact rarely affected by chemical treatments in
large-scale surveys (Hillenmeyer et al., 2008), probably because
yeast cultures in these studies are typically grown in rich medium
that contains adequate amounts of available copper. We found the
fitness profiles of strains deleted for known copper-uptake and
-metabolism genes to be unique to each compound (Fig. 2A).
Deletion of genes such as the copper transporter CTR1, the copper
chaperones ATX1 and ATX2, the copper-transporting ATPase
CCC2, the copper-zinc superoxide dismutase SOD1 and the copper-
dependent transcription factor CUP2 all caused sensitivity to
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Table 1. Small molecules and copper-metabolism phenotypes
Moleculea
Maybridge
Code Phenotypeb Copper additionc Compound structure
Neocuproine – Copper metabolism Rescue (5 µM) Phenanthroline
U0126 – Copper metabolism Lethal (5 µM) Sulfanylmethylidene-butanedinitrile
PTT – Copper metabolism not determined 1-Phenyl-3-(2-thiazolyl)-2-thiourea
BIO2A11 DP00477 Copper metabolism Partial rescue (15 µM) Thiocarbamoyl-acetamide derivative
BIO2B11 DP00750 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO2F3 CD00707 Copper metabolism Rescue (5 µM) Thio-urea
BIO2G5 CD02745 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO2H4 CD02044 Copper metabolism Partial rescue (15 µM) Thiosemicarbazone
BIO3C5 HR 00030 Copper metabolism Rescue (5 µM) Thio-urea derivate
BIO3E2 FM00217 No pigmentation Rescue (5 µM) Thiosemicarbazone
BIO5C9 PD00357 No pigmentation Rescue (5 µM) Thiosemicarbazone
BIO5F10 RDR 00803 Copper metabolism Rescue (15 µM) Thiosemicarbazone
BIO5H4 KM 09752 Copper metabolism Rescue (5 µM) Thio-urea derivate
BIO6C9 RJC 00588 Copper metabolism Rescue (5 µM) Carbamic acid
BIO6D7 RH 01646 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO6F7 RH 01676 No pigmentation Rescue (5 µM) Triazole-thiol
BIO7C11 SEW 02973 No pigmentation Rescue (5 µM) Pyridin-pyrimidinone
BIO7C9 SEW 01049 Copper metabolism Lethal (5 µM) Thiosemicarbazone
BIO7D2 RJF01673 Wavy notochord Rescue (5 µM) Pyridin-pyrminidinone
BIO7D3 S 02347 Copper metabolism Partial rescue (15 µM) 2,4-Diphenyl-2,3-dihydro-1,5-benzothiazepine
BIO7F2 RJF 01809 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
BIO7G3 S 02850 Copper metabolism Rescue (5 µM) Carbamothioyl benzamide
BIO8A7 SJC 00393 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO8C11 SPB 02722 Copper metabolism Partial rescue (15 µM) Benzoxazole derivate
BIO8F8 SPB 00258 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO9C3 SPB 05679 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
BIO9D5 SPB 07427 Copper metabolism Lethal (5 µM) Thiadiazole derivate
BIO9F4 SPB 07119 No pigmentation Rescue (15 µM) Thiosemicarbazone
CYTO10B10 SEW 06186 Copper metabolism Rescue (5 µM) Urea derivative (carboline-carboxamide)
CYTO10F4 SEW 01792 No pigmentation Rescue (15 µM) N-Hydroxy-benzamidine derivative
CYTO11A5 SPB 01039 Copper metabolism Rescue (5 µM) Triazole-thiol derivate
CYTO11B10 SPB 07027 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO11C10 SPB 07028 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO11D4 SPB 00779 No pigmentation Rescue (5 µM) Triazole-thiol
CYTO2A9 CD 02543 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO2E9 CD 03007 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO3A2 CD 06646 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
CYTO3A6 DFP 00275 Copper metabolism Rescue (5 µM) Thio-urea derivate (carbamothioyl benzamide)
CYTO4A11 JFD 00692 Copper metabolism Rescue (5 µM) Phenanthroline (cisplatin analogues)
CYTO7C6 RF01893 Copper metabolism Rescue (5 µM) N-Hydroxy-benzamidine derivative
CYTO7D2 RDR00093 No pigmentation Rescue (5 µM) Thiourea derivate
CYTO7F2 RDR00691 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO8C11 S04201 Copper metabolism Rescue (5 µM) Thio-urea/Quinazolinone derivative
CYTO8C5 RJF01649 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
CYTO9C5 S09668 Copper metabolism Partial rescue (15 µM) Thiourea derivates
CYTO9D11 S14458 Copper metabolism Rescue (5 µM) Thiosemicarbazone
aCompounds used in yeast genetic profiling are indicated in a bold font. U0126 and PTT were found in the Sigma LOPAC screening library.
bCopper-metabolism phenotype is defined as having hypopigmentation, a wavy notochord and expanded hindbrain, as described for the copper-transport atp7a-mutant zebrafish
(Mendelsohn et al., 2006) and shown in Fig. 1.
cAddition of copper chloride (5 µM or 15 µM) with the compound either rescued the copper-metabolism phenotype or caused lethality.
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chemically induced copper deficiency. Copper transport into the
cell by high-affinity transporters requires copper to be in the
reduced Cu(I) state, which is dependent on the ferric and cupric
(ferric/cupric) reductases Fre1 and Fre2 (De Freitas et al., 2003).
In yeast, and in human disease, copper and iron homeostasis are
intimately linked (De Freitas et al., 2003; van Bakel et al., 2005;
Madsen and Gitlin, 2007a). We observed that both fre1 and fre2
strains were highly sensitive to copper starvation caused by different
compounds. Finally, the iron transporters Fet3 and Fet5 are known
copper-dependent enzymes, and we found that a fet3 strain was
also highly sensitive to copper depletion. The effects of the CM
subset on specific gene-deletion strains thus reflected action of
compounds on copper homeostasis, as well as iron homeostasis
(van Bakel et al., 2005; Rustici et al., 2007).
To understand the biological processes affected by the CM
subset, we next assessed the Gene Ontology (GO) biological
processes affected by each compound (Fig. 2B; Table 2;
supplementary material Fig. S3; see Methods). Although each
chemical caused a unique fingerprint of genetic sensitivity, several
core pathways were shared by the different compounds. These
shared processes included mitochondrial translation initiation, the
Swr1 histone-remodeling complex, tubulin-complex assembly,
vacuolar organization and intracellular transport, and peroxisome
formation. Many of these pathways are linked to copper
homeostasis. For example, copper plays a vital role in
mitochondrial function, such as in cytochrome c oxidase activity
(Madsen and Gitlin, 2007b). Expression of the copper
metallothionein gene in yeast is regulated by chromatin
modification (Kuo et al., 2005), such that sensitivity of the Swr1
histone-exchange complex (Zilberman et al., 2008) to low-copper
conditions might reflect inappropriate control of metallothionein
(Kuo et al., 2005). Interestingly, loss of genes involved in threonine
biosynthesis resulted in sensitivity to some CM subset
compounds. Depletion of genes involved in the biosynthesis of
certain amino acids causes sensitivity to multiple treatment
conditions, including high-copper concentrations (Ericson et al.,
2008; Hillenmeyer et al., 2008; Jo et al., 2008). However, genes
involved in the threonine-biosynthesis pathway are not among
Disease Models & Mechanisms 643
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Fig. 2. Yeast chemical-genetic profiles of small molecules that affect copper metabolism. (A)Copper-pathway mutant strains that were specifically sensitive
or resistant to U0126, neocuproine or the CM subset compounds. At least two concentrations for each compound were used for analysis. Genes with copper-
dependent functions were compiled from Saccharomyces Genome Database (SGD, http://www.yeastgenome.org); this list includes copper-containing proteins
and known factors in copper and/or iron transport and homeostasis. Color scale indicates degrees of sensitivity (red) or resistance (green); white indicates no
data available in a given experiment. (B)Yeast chemical-genetic profiles reveal shared and distinct modes of action for CM subset compounds. A heatmap of GO
biological process categories that correlated with sensitivity (red) or resistance (green) to different compounds is shown. Two different concentrations of each
compound were screened. Scores for each GO category that contained at least four genes were calculated as the average z-score of all mutants in the category.
GO categories contained in the heatmap represent the top 2% of affected categories. GO categories with overlapping gene sets are clustered (see also Table 2).
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this known set of pleiotropic genes (Ericson et al., 2008;
Hillenmeyer et al., 2008), suggesting a previously unknown
relationship between threonine biosynthesis and copper
metabolism in yeast.
The identification of strains defective in tubulin binding and
assembly (Geissler et al., 1998) as resistant to copper starvation
revealed an unexpected link between tubulin and copper
homeostasis. Tubulins require post-translation folding, assembly
into heterodimers, and then assembly into microtubules. In vitro
and cell-based studies have shown that microtubules disassemble
in excess copper (Liliom et al., 1999; Liliom et al., 2000; Nawaz et
al., 2005; Pribyl et al., 2008; Liu et al., 2009). Copper might bind
the sulfhydral groups of microtubules and thereby block
microtubule assembly and/or induce disassembly (Wallin et al.,
1977). The GIM (genes involved in microtubule biogenesis) proteins
are highly conserved and form a complex that promotes the
formation of functional tubulins (Geissler et al., 1998). The gim
strains all have a slow-growth phenotype in rich medium, such that
the resistance of gim strains to copper limitation might reflect
reduced activity of a copper-dependent process that normally
inhibits tubulin biogenesis. This effect seems to be specific to the
gim strains because all other strains with a slow-growth phenotype
did not suppress growth defects caused by copper depletion.
Copper transport is highly regulated in the cell and involves
transport into the endoplasmic reticulum, as well as through
secretory and vacuolar pathways for delivery to copper-dependent
enzymes, copper excretion and copper detoxification (Yuan et al.,
1997; Howell et al., 2006; Gonzalez et al., 2008; Jo et al., 2008; Jo
et al., 2009). GO biological process category enrichment for cell
growth in low-copper conditions revealed the importance of the
AP1 adaptor complex, the AP3 adaptor complex, the HOPS
complex, the clathrin adaptor complex and the Golgi-to-vacuole
transport pathway. AP1, AP3 and HOPS complex subunits are
highly conserved and mutated in some human genetic disorders
(Dell’Angelica, 2009). Although disruption of the AP1, AP3 and
HOPS complexes has not previously been shown to cause sensitivity
to low-copper conditions, intracellular transport and vacuolar
pathways share some overlap with sensitivity to iron homeostasis.
For example, disruption of the AP3 adaptor complex in aps3 and
apm3 strains causes sensitivity to both low-iron and low-copper
conditions (Jo et al., 2009) (supplementary material Fig. S3). The
requirement for these pathways in the presence of low levels of
copper might reflect the inability of copper to reach essential
copper-dependent proteins, including the activity of copper-
dependent proteins in iron homeostasis, such as Fet3.
Finally, yeast gene-deletion profiles uncovered an important role
for the peroxisome in coping with copper depletion. We speculate
this dependency arises because the copper-zinc SOD is a
constituent enzyme of the peroxisome matrix, which is essential
for its dismutase and peroxidase function (Titorenko and Mullen,
2006; Islinger et al., 2009). Deletions in other peroxisomal genes
have also recently been shown to sensitize to low-iron conditions,
possibly because of an elevated requirement for peroxisomal -
oxidation in energy production when iron-dependent
mitochondrial energy production is impaired (Jo et al., 2009). A
similar effect might occur upon copper deficiency because copper
is also essential for mitochondrial functions and iron homeostasis.
Notably, human disorders of peroxisome biogenesis such as
Zellweger syndrome are characterized in part by high levels of
copper and iron in blood and tissues (Wanders and Waterham,
2005).
The MEK inhibitor U0126 elicits an unexpected copper-
metabolism phenotype
The identification of U0126 in our zebrafish phenotypic screen is
consistent with a recently suggested role for this MEK inhibitor in
copper metabolism (Hawkins et al., 2008). Although U0126 partially
phenocopies the atp7a-mutant zebrafish, the speculative link
between MEK signaling and copper pathways has not been
investigated (Hawkins et al., 2008). We thus set out to determine
whether the copper-metabolism phenotype induced by U0126 in
zebrafish development and in yeast chemical-genetic profiles was
directly due to inhibition of MEK activity or whether U0126 might
have an additional target in copper homeostasis independent of its
activity as a MEK inhibitor.
We compared the U0126-induced phenotype with those
induced by the selective MEK inhibitor PD0325901 and the known
copper chelator neocuproine (Fig. 3A). In vitro kinase-inhibition
profiles suggest that the MEK inhibitors CI-1040 and PD0325901
are the most highly selective inhibitors of MEK activity, as
compared with U0126 and other commercially available
compounds (Davies et al., 2000; Sebolt-Leopold, 2008). Despite
dmm.biologists.org644
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Table 2. Genes within Gene Ontology (GO) category biological processes in Fig. 2
GO category Genes
Histone H3-K4 methylation BRE2, SDC1, SHG1, SPP1, SWD1, SWD3
Protein import into
peroxisome matrix
DJP1, PEX10, PEX12, PEX18, PEX2, PEX21, PEX25, PEX13, PEX14, PEX17, PEX5, PEX7, PEX1, PEX15, PEX22, PEX4, PEX6
Tubulin-complex assembly GIM3, GIM4, GIM5, PAC10, RBL2, YKE2
Golgi-to-vacuole transport APL2, APL4, APL5, APL6, APM1, APM2, APM3, APS1, APS3, GGA1, GGA2, PEP12, PEP7, TLG2, VAM3, VAM7, VPS52| VPS53, VTH1, YPT7
Swr1 complex  ARP6, SWC3, SWC5, SWC7, SWR1, VPS71, VPS72, YAF9
GID complex FYV10, GID7, GID8, RMD5, VID24, VID30
-subunit complex
(proteasome core complex)
PRE10, PRE5, PRE6, PRE8, PRE9, PUP2, SCL1
Lid subcomplex (proteasome
regulatory particle)
RPN3, RPN5, RPN6, RPN7, RPN8, RPN9, RPN10, RPN11, RPN12, RPN13, SEM1
Base subcomplex (proteasome
regulatory particle)
RPT1, RPT2, RPT3, RPT4, RPT5, RPT6, RPN1, RPN10, RPN12
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the fact that the RAS-RAF-MEK-ERK signaling pathway plays an
important role in melanoma development in humans, mice and
zebrafish, we found that neither CI-1040 nor PD0325901 affects
melanocyte pigmentation in zebrafish development (Fig. 3A) (see
also Grzmil et al., 2007; Anastasaki et al., 2009). This result
suggests that selective inhibition of MEK activity does not affect
pigmentation in zebrafish melanocytes, and that the similarity
between the U0126-induced phenotype and the atp7a-mutant
phenotype most likely reflects a previously undetected additional
target pathway for U0126 in copper homeostasis. Like
neocuproine, U0126 also causes a loss of blood development in
the embryo and an undulating notochord (Fig. 3A,B). In support
of the hypothesis that U0126 can directly affect copper
metabolism, we found that U0126, but not CI-1040, avidly binds
copper in aqueous solution (Fig. 3C; supplementary material Fig.
S4). Thus, despite its frequent use as a specific inhibitor of MEK
kinase activity, our analysis based on pigment formation in
zebrafish has identified a novel action for U0126 in vivo.
Western blotting of extracts from treated zebrafish embryos with
an anti-phospho-ERK antibody confirmed that PD0325901 and
U0126 both effectively inhibit MEK activity during development,
whereas neocuproine had no obvious inhibitory effect on phospho-
ERK levels in zebrafish (Fig. 3D) or in human cells (supplementary
material Fig. S7). PD0325901 was a substantially more potent
inhibitor than U0126 as a 2-hour treatment was sufficient to
strongly inhibit ERK activity (Fig. 3D). To study the U0126-induced
pigmentation phenotype in more detail, we mapped the timing of
action of U0126 on developing melanocytes (Fig. 3E). In zebrafish
development, melanocytes develop from the neural crest and
become pigmented at about 28 hpf. Treatment with U0126 after
21 hpf did not affect normal melanocyte pigmentation, whereas
treatment before 21 hpf prevented pigmentation; this effect was
not a permanent developmental defect as melanocyte pigmentation
rapidly recovered after U0126 wash-out (Fig. 3E). By electron
microscopy, we also found evidence of fewer and less-dense
melanosomes in melanocytes of embryos treated with 5 M of
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Fig. 3. Phenotype elicited by U0126 treatment in zebrafish embryos. (A)U0126 phenocopy of neocuproine (neo) in 2-day-old zebrafish embryos. As a
control, the more selective MEK inhibitor PD0325901 did not affect pigmentation but instead prevented development of posterior features. (B)U0126 caused
blood loss as detected by o-dianisidine (red) staining. (C)U0126 and neocuproine complex with copper, as indicated by color change upon addition to aqueous
copper chloride solution. (D)Inhibition of MEK activity in vivo. Lysates from 12-hpf zebrafish embryos were assessed for phospho-ERK and phospho-MEK levels
after treatment with PD0325901 (PD) and U0126 (U0). Note inhibitor treatment is known to increase phospho-MEK (Pratilas et al., 2009). A short (2-hour)
treatment (asterisk) with PD0325901 also reduced phospho-ERK levels in zebrafish embryos, demonstrating the elevated potency of PD0325901. (E)U0126
(10M) treatments prevent pigmentation when administered before 21 hpf. When administered at 21 hpf or later, the embryos develop pigment at about
28 hpf, similar to untreated zebrafish embryos. U0126 treatments are each represented by a barline, and the color of the barline represents the color of the
zebrafish melanocytes. The effects on pigmentation are reversible, and pigmentation can rapidly recover from U0126 treatment. For example, U0126-treated
unpigmented 33 hpf zebrafish embryos recover pigmentation 4 hours after shifting to fresh embryo medium (asterisk). These phenotypes are consistent with a
role for U0126 in blocking the copper-dependent pigmentation enzyme, tyrosinase (Rawls and Johnson, 2000). (F)Electron microscopy of 2-day-old untreated
and U0126-treated (5M) zebrafish embryos reveals smaller and less densely pigmented melanosomes in the latter.D
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U0126 (Fig. 3F). The timing of action of U0126 on melanocyte
pigmentation is consistent with the known kinetics of appearance
of the rate-limiting copper-dependent enzyme tyrosinase in
development (Hultman and Johnson, 2010).
We compared the genome-wide chemical-genetic profiles of
U0126, CI-1040 and neocuproine to determine the potential target
pathways of U0126. These profiles revealed that 13 deletion strains
were sensitive to both U0126 and neocuproine, and that 12 deletion
strains exhibited shared sensitivities to U0126 and CI-1040 (Fig.
4A). By contrast, only the pex10 strain was sensitive to both CI-
1040 and neocuproine, and only the yaf9 strain was sensitive to
all three compounds. Therefore, although U0126 has a partially
overlapping chemical-genetic fingerprint with CI-1040 and
neocuproine, CI-1040 and neocuproine have overtly different
activities. These profiles are fully consistent with the shared
molecular phenotype between U0126 and CI-1040 of inhibition of
ERK phosphorylation in zebrafish lysates (Fig. 3D), and the shared
developmental and chemical phenotype between U0126 and
neocuproine (Fig. 3A).
Comparison of GO biological processes (Table 2) affected by the
different inhibitors revealed both shared and distinct processes.
Disruption of the peroxisome and the Swr1 histone-exchange
complexes caused sensitivity to both U0126 and neocuproine (Fig.
4B). Impaired intracellular transport and the function of the
proteasome 19S regulatory particle compromised growth only in
the presence of neocuproine. Loss of the GID ubiquitin ligase
complex reduced growth in the presence of U0126, whereas
disruption of tubulin-binding processes actually led to resistance
in the presence of U0126 (Fig. 4B). A comparison of GO processes
affected by the CM subset compounds and CI-1040 allowed us to
determine whether the U0126 target pathways were due to copper-
dependent pathways, MEK pathways or additional target pathways.
Whereas CI-1040 and neocuproine had no effect on tubulin
binding and tubulin-complex assembly, treatment with SPB07427,
DP00477, JFD00692 and RJF01649 caused resistance of strains
defective in tubulin binding and tubulin-complex assembly. Given
the shared zebrafish and yeast phenotypes between U0126 and
these compounds, it seems that U0126 acts on tubulin-associated
processes via alterations in copper metabolism. Notably, in contrast
to the shared chemical profiles between U0126, neocuproine and
CI-1040, mutations in all six components of the GID complex
resulted in high sensitivity to U0126 (Fig. 3B, Fig. 4B). The GID
complex is an E3 ubiquitin ligase that targets a key enzyme in
gluconeogenesis, fructose 1,6-bisphosphatase (FBPase), for
proteasomal degradation (Santt et al., 2008). With the exception
of neocuproine, the GID complex also showed sensitivity to CM
subset compounds, albeit most strongly with U0126 (Fig. 2;
supplementary material Fig. S3). The GID complex might thus
represent a new target of copper metabolism in yeast. Collectively,
these data reveal new copper-dependent target pathways for U0126,
which have remained cryptic despite the extensive use of U0126
in biochemical and cell biological assays in many different signaling
contexts.
Knockdown of trafficking components sensitizes zebrafish to
copper-dependent hypopigmentation
Intracellular transport pathways, although essential for all cells, have
a specific role in melanosome biogenesis. Pigmentation enzymes
and the copper transporter ATP7A are selectively transported from
the trans-Golgi network to the maturing melanosomes (Raposo and
Marks, 2007; Setty et al., 2008). To test whether the genes that affect
copper sensitivity in yeast might inform about relevant copper
pathways in melanocytes, we selected two genes that had orthologs
in zebrafish for knockdown by morpholino oligonucleotides (MOs)
in the developing embryo. For this purpose we designed MOs
against genes that encode a component of the AP1 transport
complex (APS1 in yeast, ap1s1 in zebrafish) and a component of
the AP3 transport complex (APS3 in yeast, ap3s2 in zebrafish)
dmm.biologists.org646
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Fig. 4. Novel target pathways for the
MEK inhibtior U0126. (A)Heat map of
deletion strains that are sensitive (red) or
resistant (green) to U0126, neocuproine
and CI-1040. U0126 shares a chemical
profile with neocuproine and with CI-
1040, whereas neocuproine and CI-1040
do not share a common profile.
(B)Neocuproine (yellow), U0126 (green)
and CI-1040 (blue) treatment affect
common and distinct biological
processes. GO categories were examined
for each of the deletion mutants that
were affected by each compound (see
Table 2). The genes in a specific GO
category were compared with the
number of strains actually affected by
each compound and the P values
determined. Only GO categories with
more than four genes were examined and
only P values <0.05 were considered.
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(supplementary material Fig. S5). We separately injected a splice-
site MO designed against ap3s2 (ap3s2-MO1) and a translation-
blocking MO designed against ap1s1 (ap1s2-MO1) (Montpetit et
al., 2008) into single-celled zebrafish embryos and monitored
development in low-neocuproine conditions. Splice-site MOs were
verified by PCR analysis (supplementary material Fig. S6). At low
MO concentrations (1-3 pg), the ap1s1 and ap3s2 morphants
developed normally to at least 2 days pf (Fig. 5A). Next, we treated
4-6 hpf morphants with a range of neocuproine concentrations (1
M, 2 M and 5 M) and followed the development of the treated
animals over 2 days. Without neocuproine, neither the uninjected
controls nor the morphant animals displayed any of the principal
features of developmental copper deficiency, including reduced
pigmentation, a buckling notochord or an expanded hindbrain (Fig.
5A). This result suggests that under optimal nutrition conditions,
partial reduction of ap1s1 or ap3s2 function does not affect
development of the zebrafish embryo. At 5 M neocuproine,
developing wild-type and morphant embryos exhibited features of
developmental copper-metabolism deficiency, which could be
prevented with the addition of exogenous copper chloride at a
concentration of 5 M (Fig. 5A). At intermediate neocuproine
concentrations (1 M, 2 M), we often observed severe
hypopigmentation in the ap3s2 morphants (n37/71 embryos),
whereas control animals exhibited only a mild (at 1 M) to
moderate (at 2 M) reduction in melanocyte pigmentation (n>100).
The ap1s1 morphants also displayed melanocyte pigmentation
sensitivity at 1 M neocuproine (n13/39) compared with the
control-treated animals. A similar effect was seen using the splice-
site MOs ap3s2 (ap3s2-MO2) and ap1s1 (ap1s1-MO2) (see
Methods). Thus, at least two of the yeast intracellular transport
pathways that affected sensitivity to the CM subset compounds
proved to be physiologically relevant in the developing vertebrate.
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Fig. 5. Identification of two new gene-nutrient interactions in melanocyte pigmentation. Morpholino oligonucleotides (1-3 pg) directed against ap1s1 and
ap3s2 result in morphants with normal development and pigmentation. Higher concentrations of ap1s1-MO have been reported to cause pigmentation
phenotypes (Montpetit et al., 2008). Treatment with 5M neocuproine caused a copper-deficiency phenotype in all animals that could be rescued with the
addition of 15M copper chloride. At a concentration of 1.0M neocuproine, copper limitation caused a loss of pigmentation in the ap3s2 morphants compared
with control-treated embryos, and a severe loss of pigmentation at 2M neocuproine, compared with mild (1M) to moderate (2M) loss of pigmentation in
control animals. A milder pigmentation phenotype was also visible in the ap1s1 morphants treated with 1M neocuproine. Experiments were repeated multiple
times (more than three times for each morpholino; n>20 per treatment), and similar results could be obtained with an additional splice-site MO designed to
target each gene (see Methods). (B)Simplified schematic of gene-copper interactions in a zebrafish melanocyte. Partial reduction of AP3 complex activity (such
as in the ap3s2 morphant; represented by a dotted line) retains sufficient AP3 activity for melanosome pigmentation in optimal-copper nutrient conditions, and
the melanocyte is darkly pigmented. Likewise, melanocytes with normal AP3 activity in suboptimal-copper nutrient conditions retain the ability to generate
pigment. By contrast, in low-copper nutrient conditions, reduced AP3 function is no longer sufficient for promoting proper melanosome maturation, and the
melanocytes are hypopigmented. Cu, copper; E, endosomal bodies; G, trans-Golgi network; M, melanosomes.
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DISCUSSION
Identification of the allelic variants that underlie gene-nutrient
interactions is important for understanding the genetic differences
between individuals that contribute to disease susceptibility (Thiele
and Gitlin, 2008). We used the zebrafish and yeast model systems
to identify small molecules that affect copper metabolism, to
uncover conserved cognate genetic pathways that sensitize to
copper deficiency and to test physiological relevance of these
pathways in zebrafish (Fig. 1A). The identification of the dual targets
of the commonly used MEK inhibitor U0126 underscores the power
of a combined zebrafish and yeast platform to elucidate multiple
target pathways of small molecules in vivo.
The conservation of copper-metabolism pathways in yeast,
zebrafish and humans suggests that our analysis of genetic
sensitivities to copper limitation can provide insight into the
molecular pathogenesis of hypocupremia. Comparison of the
chemical profiles of the five copper chelators identified by
phenotypic screening, as well as neocuproine and U0126, revealed
a substantial overlap in target pathways, including intracellular
transport pathways. Intracellular trafficking is crucial for transport
of copper to copper-dependent enzymes, recycling of the copper
transporter ATP7a, and also for copper detoxification in
environments of high copper concentrations (Jo et al., 2008). In
melanocytes, ATP7A itself is transported to maturing melanosomes
in order to restrict the activation of copper-dependent pigmentation
enzymes, such as tyrosinase, to this specialized structure (Setty et
al., 2008). Tyrosinase, as well as other pigmentation enzymes, is
selectively transported to the maturing melanosome by components
of the AP1 and AP3 complex; another transporter, the BLOC-1
complex, is required for the selective transport of ATP7A (Wei,
2006; Raposo and Marks, 2007). Known but rare alleles of the AP3
gene give rise to the disorder HPS, and AP1s1 components are
mutated in a neurocutaneous syndrome that is characterized by
mental retardation, enteropathy, deafness, peripheral neuropathy,
ichthyosis and keratodermia, termed MEDNIK. Our yeast and
zebrafish data suggest that reduced but otherwise functional levels
of AP1 and AP3 that have no effect on pigmentation in optimal
nutritional conditions can cause dramatic effects on pigmentation
under reduced-copper nutrition conditions (Fig. 5B). The
combination of zebrafish and yeast screens might be particularly
suited to detection of gene-environment interactions in vertebrates
that are characterized by allelic variants of modest quantitative
effect (Manolio et al., 2009).
Phenotypic and genome-scale genetic analysis in model
organisms is an effective method for identifying new target
pathways for known and novel compounds. A major question in
chemical biology is how a chemically induced phenotype relates
to the in vivo mechanism of compound action and how this
knowledge can be exploited to predict off-target effects.
Biochemical, in silico and cell-based methods are usually applied
in an effort to identify molecular targets, but these approaches can
often fail because of limitations in sensitivity and specificity.
Predicted drug-target associations of 3665 US Food and Drug
Administration (FDA)-approved drugs and other pharmaceutical
agents correctly identified 23 new molecular targets for known
drugs (Keiser et al., 2009). However, a molecular target under a
specific experimental context does not always reflect the action of
the compound within the complexity of the developing animal, as
illustrated by the unexpected copper-dependent effects of the MEK
inhibitor U0126 in our study. Although not all processes or genes
are conserved between yeast, zebrafish and human, we note that
complex disease states often converge on highly conserved gene
networks (Tan et al., 2009), suggesting that the zebrafish-yeast
screening approach might be applicable to many other human
genetic diseases. To our knowledge, our study is the first to
explicitly couple phenotype-based screens in zebrafish to genome-
wide chemical-genetic profiles in yeast in order to identify gene-
environment interactions during animal development. This
approach holds promise for interogating networks of gene-
environment interactions in other complex human genetic diseases.
METHODS
Zebrafish husbandry and phenotypic screening
Zebrafish were raised and maintained in compliance with the
Animals (Scientific Procedures) Act 1986 of the UK. Embryos were
acquired by pair breedings of wild-type AB, AB* and TL zebrafish
lines. For small-molecule screening, two 4-hpf zebrafish embryos
were arrayed in 96-well plates, and 300 l of E3 embryo medium
(Westerfield, 2000) with 10 M of compound in 1% DMSO was
added. Compounds were from the LOPAC (1280) Small Scale
International Version (Sigma-Aldrich) and a subselection of the
Maybridge screening collection (Fisher Scientific International).
Embryos were assessed and imaged for phenotypic changes at 28
hpf, 36 hpf, 48 hpf and 56 hpf. Small molecules that prevented
pigmentation, and caused an expanded hindbrain and a wavy
notochord, were classed as having a copper-metabolism phenotype.
The classification was confirmed by treating developing embryos
with freshly prepared compound in the presence or absence of
excess copper chloride at concentrations of 5 M and 15 M. CI-
1040 was kindly provided by Richard Marais (London, UK) and
PD0325901 was obtained from Hilary McLauchlan (University of
Dundee, UK). Embryos were treated with 10 M or 25 M
neocuproine or U0126 and 1 M or 2.5 M PD0325901 at different
developmental stages. To inhibit pathway activity during
development, 4 hpf embryos were treated with compounds
continuously until 12 hpf; acute effects were assessed using a pulse
of compound from 10 hpf to 12 hpf.
Western blotting
Embryos (12 hpf) were frozen at –80°C after removal of the embryo
buffer. Samples were lysed in RIPA buffer [2 M Tris pH 7.5, 5 M
NaCl, 1% NP40, Na-deoxycholate, 10% SDS, 0.5 M NaF, 1 M -
glycosyl phosphate and protease-inhibitor cocktail tablet (Roche)].
Samples were normalized by protein as measured by Bradford assay,
separated by SDS-PAGE, transferred to Hybond-C Extra
nitrocellulose membrane (Amersham Biosciences), probed with
rabbit [p44/42 MAPK (1:2000) and phospho-MEK1/2 (Ser217/221)
(1:500) (Cell Signaling Technology)] or mouse [phospho-p44/42
MAPK (E10) (1:2000), alpha-tubulin B-5-1-2 (1:50,000) (Santa
Cruz)] antibodies and detected with horseradish-peroxidase-
conjugated secondary antibodies (Roche).
Electron microscopy
Embryos were fixed with 2.5% glutaraldehyde, 2%
paraformaldehyde in 100 mM cacodylate buffer (pH 7.2) with 2
mM MgCl2 and 0.1% picric acid. Following a wash with 200 mM
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cacodylate buffer, samples were fixed with 1% osmium tetroxide
in 100 mM cacodylate buffer (pH 7.0), washed with distilled water,
stained en bloc with 0.5% aqueous uranyl acetate, and dehydrated
with ethanol. Samples were embedded in Agar 100 resin and
sections were cut, stained with lead citrate and viewed on a FEI
Tecnai 12 transmission electron microscope.
Yeast chemical-genetic profiles
The MATahaploid and the essential heterozygous yeast deletion sets
were obtained from Research Genetics (Germany). Chemical-genetic
profiles were generated essentially as described (Giaever et al., 2002).
Briefly, for growth-inhibition screens, 5-ml pool cultures were
seeded at an OD600 of 0.025 and compound (or DMSO for control
samples) was added after a 2-h pre-growth period. Compound
concentrations were selected to inhibit pool growth by 20-30%
compared with DMSO controls at 12 hours; cultures were diluted
back to an OD600 of 0.025 twice with addition of fresh compound
to allow growth for a total of 20 generations. Each compound was
screened at two different concentrations (supplementary material
Table S1). The final concentration of DMSO was 0.4% for all screens.
Genomic DNA was isolated for control and experimental pools,
barcodes were amplified with fluorescently labeled primers, and PCR
products were hybridized to in-house short-oligonucleotide
microarrays (Cook et al., 2008). A GenePix 4200AL was used to scan
the slides, and hybridization intensity for each spot was determined
using GenePix Pro 6.0 software.
Identification of sensitive and resistant mutant strains
The identification of sensitive and resistant strains in the chemical-
genetic screens was performed using R and limma, an R package
for the analysis of gene expression microarray data. Spots with low
intensity and low quality were excluded from further analysis.
Intensities of duplicate spots for each barcode on the array were
averaged. z-scores for up and down barcode tags were calculated
based on log2 fold-change ratios (compound treated vs DMSO
control): z(x-)/s where  is the mean log2-fold change for all up
or down barcodes on an array and s is the standard deviation. The
two barcode scores were averaged for each deletion strain to give
the final z-score. Microarray raw data and z-scores for each mutant
were stored in a custom MySQL database. Standard procedures
for z-score and quantile-based statistics for microarray data were
used to identify sensitive and resistant deletion strains
(Quackenbush, 2002; Cheadle et al., 2003). The microarray data
are available at ArrayExpress (accession number E-TABM-922).
Assignment of GO biological process terms
Instead of relying on arbitrary cut-offs to define enriched sets of
deletion strains that were most affected by treatment with the
compounds, we calculated average z-scores for all GO biological
process categories in each experiment for GO categories that
contained data for at least four genes. Quartile-based statistics were
used to identify significantly affected GO biological processes
(Saccharomyces Genome Database, http://www.yeastgenome.org,
release 02/07/2009).
Morpholino oligonucleotides
The MOs were designed by GeneTools (USA) and prepared as a
1 mM stock solution in water. For Fig. 5A, 1-3 pg was injected into
each one-cell stage embryo. MO sequences were designed to block
splicing for a zebrafish ortholog of the yeast gene APS3, called ap3s2
(Ensembl(Zv8): ENSDARG00000039882) (ap3s2-MO1: 5-
TGCAA AAGCCTCTCCATCACCTTCC-3). Confirmation of
ap3s2-MO1 activity was determined by PCR with primers AP3S2-
F1 [5-TCAACAACCATGGGAAACCC-3 (forward primer)]
and  AP3S2-R1 [5-TGACTGCAGAAACGGCTCG-3 (reverse
primer)]. Inclusion of intron 2 was determined by sequencing of
the longer cDNA product. A translation-block MO for ap1s1
(Ensembl(Zv8): ENSDARG00000056803), an ortholog of APS1, was
directly purchased from GeneTools (ap1s1-MO1: 5-ACAGA -
AGCATAAAGCGCATCATTTC-3), and has been previously
verified by western blotting morphant embryo extracts with an
antibody (Montpetit et al., 2008). Two additional splice-site
MOs  were designed and ordered from GeneTools: ap3s2-MO2
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TRANSLATIONAL IMPACT
Clinical issue
Genetic differences contribute to the variation among individuals in coping
with environmental stresses, such as nutritional deficiency. Copper is an
essential nutrient, and disorders of copper metabolism can lead to severe
neuronal, muscular and pigmentation clinical symptoms. Genetic mutations in
the copper transporter ATP7A lead to a copper-deficiency syndrome called
Menkes disease, and copper deficiency can also develop after intestinal bypass
surgery or an excess intake of iron. However, many causes of copper deficiency
are unknown, and genetic factors might contribute to the sensitivity of some
individuals to reduced nutritional availability of copper. 
Results
Many crucial enzymes require copper as a cofactor, and melanocytes have a
specific requirement for copper in the maturation of pigmented melanosomes.
Here, the authors use a zebrafish- and yeast-based approach to identify
genetic pathways that modulate melanocyte pigmentation in conditions of
copper nutritional deficiency. First, they carry out a chemical screen for small
molecules that affect copper homeostasis in zebrafish on the basis of a
hypopigmentation phenotype. Next, they use budding yeast to systematically
map the genetic pathways that underlie sensitivity to the small molecules
identified in the zebrafish-based chemical screen. They then demonstrate that
two genes encoding intracellular transport proteins identified in the yeast
genetic screen are physiologically relevant, as their zebrafish orthologs, aps1s
and ap3s2, are involved in sensitizing zebrafish melanocytes to
hypopigmentation in conditions of mild copper deficiency. Notably, the
authors also use the zebrafish-yeast approach to identify an off-target effect
for a small molecule commonly used in cell-signaling studies, the MEK
inhibitor U0126, which was previously not known to affect pathways of copper
metabolism.
Implications and future directions
The copper-gene interactions identified in this study illustrate the larger issue
of how disease susceptibility can be underpinned by complex environment-
gene interactions. This zebrafish-yeast approach will be applicable to the
dissection of many complex disease-gene networks, particularly because such
networks are enriched for highly conserved genes. This approach is also well
suited for investigating gene-environment interactions, which are a challenge
to assess given that modest genetic effects can be difficult to identify through
classical quantitative methods. Importantly, the zebrafish-yeast approach
provides a systematic means by which to elucidate the in vivo actions of small
molecules in a vertebrate system, which is a challenge in chemical biology
applications. Finally, the identification of copper-metabolism pathways in
zebrafish is a starting point for exploring the role of analogous pathways in
human diseases of copper deficiency. 
doi:10.1242/dmm.006205
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(5-TGCAGTTACGTTCACCTGTATAAGA-3) and ap1s1-MO2
(5-GACTAGCATACCTACGTAAACACAC-3) (Montpetit et al.,
2008). Confirmation of ap3s2-MO2 activity was determined by PCR
with primers AP3S2-F2 [5-TGCAGCAGCAGATCATCAGGG-3
(forward primer)] and AP3S2-R2 [5-GACTGTCAGTAATGG -
CAAGAGG-3 (reverse primer)]. Results were consistent with both
MOs for each gene, with greater effects seen with increasing
concentration of MO (5-10 pg). All MOs were labeled with a
florescent tag and assessed for even MO distribution throughout
the embryo. Changes in pigmentation were assessed by two or three
individuals who scored the phenotypes blinded to the MO
genotypes.
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